0001628280-24-010279.txt : 20240311 0001628280-24-010279.hdr.sgml : 20240311 20240311171952 ACCESSION NUMBER: 0001628280-24-010279 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240311 FILED AS OF DATE: 20240311 DATE AS OF CHANGE: 20240311 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Mostafa Adam S. CENTRAL INDEX KEY: 0001738081 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38295 FILM NUMBER: 24739162 MAIL ADDRESS: STREET 1: C/O X4 PHARMACEUTICALS INC. STREET 2: 61 NORTH BEACON STREET, 4TH FLOOR CITY: BOSTON STATE: MA ZIP: 02134 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: X4 Pharmaceuticals, Inc CENTRAL INDEX KEY: 0001501697 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 273181608 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 61 NORTH BEACON STREET STREET 2: 4TH FLOOR CITY: BOSTON STATE: MA ZIP: 02134 BUSINESS PHONE: 857-529-8300 MAIL ADDRESS: STREET 1: 61 NORTH BEACON STREET STREET 2: 4TH FLOOR CITY: BOSTON STATE: MA ZIP: 02134 FORMER COMPANY: FORMER CONFORMED NAME: Arsanis, Inc. DATE OF NAME CHANGE: 20100920 4 1 wk-form4_1710191979.xml FORM 4 X0508 4 2024-03-11 0 0001501697 X4 Pharmaceuticals, Inc XFOR 0001738081 Mostafa Adam S. C/O X4 PHARMACEUTICALS, INC. 61 NORTH BEACON STREET, 4TH FLOOR BOSTON MA 02134 0 1 0 0 Chief Financial Officer 0 Common Stock 2024-03-11 4 S 0 52500 0.8828 D 0 D The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $0.8649 to $0.9147, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. These transactions were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 23, 2023. /s/ Paula Ragan, attorney-in-fact 2024-03-11